Scarica l'app Stockscreener
985.08
0.80%
7.83
Dopo l'orario di chiusura:
984.01
-1.07
-0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$977.25
Aprire:
$980.13
Volume 24 ore:
1.98M
Relative Volume:
0.64
Capitalizzazione di mercato:
$879.67B
Reddito:
$65.18B
Utile/perdita netta:
$20.64B
Rapporto P/E:
43.61
EPS:
22.5894
Flusso di cassa netto:
$5.96B
1 W Prestazione:
-0.53%
1M Prestazione:
-5.28%
6M Prestazione:
+30.41%
1 anno Prestazione:
+22.88%
Intervallo 1D:
$978.00
$1,003.22
Intervallo di 1 settimana:
$973.16
$1,012.00
Portata 52W:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
985.08 | 879.67B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.52 | 582.04B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.68 | 388.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
189.90 | 294.50B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.44 | 292.79B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
The Pill War Heats Up: Novo Relies On Wegovy To Reclaim Leadership From Eli Lilly - Emirates 24|7
Roche’s breast cancer failure; BioNTech co-founders to depart; Eli Lilly’s quest to stay on top; and more - Endpoints News
Harvest Fund Management Trims Eli Lilly Stake - National Today
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline - AOL.com
Eli Lilly Stock Pulls Back from January Peak as Valuation Pressures Mount - AD HOC NEWS
Is Eli Lilly's Weight Loss Empire in Trouble? - AOL.com
Is Eli Lilly's Weight Loss Empire in Trouble? - The Motley Fool
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm - FinancialContent
Jim Cramer on Eli Lilly: “We’re Not Budging, We’d Buy More If It Really Got Hit” - Insider Monkey
Kroger Shares Rise, Pharmacies Add Eli Lilly Zepbound KwikPenKroger (NYSE:KR), Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly Boosts Chinese Manufacturing Investments - advancedmanufacturing.org
Kroger Says Eli Lilly's Zepbound KwikPen Now Available at Participating Pharmacies - marketscreener.com
Kroger to Offer Eli Lilly's Zepbound KwikPen With Expanded Access to Savings Program - 富途牛牛
Novo regained weight loss footing in the pill arena — but Lilly is coming - PharmaVoice
Form Health Joins the Lilly Employer Connect Platform - Business Wire
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - 富途牛牛
Why this $6.3-billion money manager is buying Eli Lilly and selling a software firm - The Globe and Mail
Eli Lilly’s China Bet On Orforglipron Reshapes Obesity Drug Narrative - simplywall.st
Eli Lilly tops growth factor grades among S&P healthcare holdings (LLY:NYSE) - Seeking Alpha
Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November - Seeking Alpha
Will Policy Shifts Accelerate Demand for Eli Lilly's GLP-1 Drugs? - sharewise.com
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12 - Benzinga
Lilly Flags Safety Risk In Compounded GLP 1 - GuruFocus
Eli Lilly Stock Slips After Warning on Compounded GLP-1 Drugs With Additives - GuruFocus
Jim Cramer Answered Questions About 13 Stocks: Eli Lilly, Meta, and More - Insider Monkey
Eli Lilly finds impurity in compounded tirzepatide - Pharmaceutical Technology
Lilly Flags Safety Risk in Compounded Zepbound Mixed With Vitamin B12 - Insurance Journal
Health risk alert as weight-loss jab manufacturer issues warning - The Independent
In latest compounding clash, Lilly flags high levels of 'impurity' in tirzepatide knockoffs with vitamin B12 - Fierce Pharma
Eli Lilly to invest $125m in Japan plant to boost supply of new drugs - Nikkei Asia
Eli Lilly (LLY) Warns Against Compounded Tirzepatide Products - GuruFocus
KLCM Advisors Inc. Sells 5,592 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Issues Warning on Safety Concerns of Compounded Tirzep - GuruFocus
Roberts Capital Advisors LLC Makes New Investment in Eli Lilly and Company $LLY - MarketBeat
Health: Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks - Gulf Daily News
Eli Lilly Expands China Production for Weight Management Drugs | 2026News and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Eli Lilly and Company finds impurity in compounded diabetes and obesity drug knockoffs - Traders Union
Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks - Reuters
An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 - Eli Lilly and Company
Eli Lilly to invest USD 3bn in China - medwatch.com
PHARMARON Surges 12%+ After Reaching Production Co-op Agreement with Eli Lilly for Orforglipron - AASTOCKS.com
Pharmaron opens higher after reaching a production cooperation agreement for Orforglipron with Eli Lilly and Co. - 富途牛牛
Lilly to Invest $3 Billion in China to Boost Obesity Pill - Bloomberg.com
Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in three additional markets in Asia - The Manila Times
Eli Lilly Ordered To Arbitrate Alzheimer's Drug Feud - Law360
Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro - Insider Monkey
Lilly Warns Some Medicare GLP-1 Costs Could Exceed $50 - GuruFocus
As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026 - Fierce Pharma
Lilly introduces direct-to-employer program for weight-loss drug - Indianapolis Business Journal
Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma
Eli Lilly to invest $3bn in China in anticipation of orforglipron approval - Pharmaceutical Technology
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):